Novel target and treatment agents for natural killer/T-cell lymphoma

Journal of Hematology & Oncology

Review

Jin-Ni Wang¹  Jia-Hui Wang¹  Qing-Qing Cai¹  Jun Cai¹  Yu-Chen Zhang¹  Qi-Hua Zou¹  Xiao-Peng Tian¹  Yu Fang¹  Song-Bin Guo¹  Yi Cao¹ 

[1] Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, No. 651, Dongfeng Road East, 510060, Guangzhou, People’s Republic of China;State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China;

关键词: Natural killer/T-cell lymphoma;    Targeted therapy;    Immunotherapy;    Novel agents;   

DOI  :  10.1186/s13045-023-01483-9

 received in 2023-06-20, accepted in 2023-07-19,  发布年份 2023

来源: Springer

【 摘 要 】

The rapidly increasing use of high-throughput screening had produced a plethora of expanding knowledge on the molecular basis of natural killer/T-cell lymphoma (NKTCL), which in turn has revolutionized the treatment. Specifically, the use of asparaginase-containing regimens has led to substantial improvement in survival outcomes in NKTCL patients. Novel treatment strategies that are currently under development include cell-surface-targeted antibodies, immune checkpoint inhibitors, Epstein-Barr virus targeted cytotoxic T lymphocyte, immunomodulatory agents, chimeric antigen receptor T cells, signaling pathway inhibitors and epigenetic targeted agents. In almost all cases, initial clinical studies of newly developed treatment are conducted in patients relapsed, and refractory NKTCL due to very limited treatment options. This review summarizes the results of these novel treatments for NKTCL and discusses their potential for likely use in NKTCL in a wider setting in the future.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 5

Fig. 2

Fig. 1